Objective: Oral precancerous lesions are one of the most prevalent lesions worldwide today. Leukoplakia is the commonest premalignant lesion, which if neglected can be fatal. Several therapeutic agents have been tried to intervene. Of which, Lycopene has been tried, tested and accepted as a conventional form of treating leukoplakia. Curcumin, [1,7-bis-(4-hydroxy-3- ethoxyphenyl)-1,6- heptadiene-3,5-dione] is regarded as the most organically active ingredient of the spice turmeric, consisting 2–8% of most turmeric preparations. It has anti-oxidant, anti- nflammatory and pro-apoptotic activities. The purpose of the study was to compare the anti- recancerous activities of lycopene with curcumin. Methodology: A randomized clinical trial was designed with 20 patients, equally distributed into Group A and Group B. Group A was administered lycopene while Group B patients were treated with Curcumin. The study subjects were followed up for three months, regularly at 15 days intervals, during which they were counselled to quit the habit. Results: A significant improvement was noted in both the groups in terms of decrease in size of lesions and cure of lesions. Conclusion: Curcumin can be used to treat oral leukoplakia as effectively as lycopene. 

Keywords: Oral Leukoplakia; Lycopene; Curcumin; Anti-Cancer; Oral Precancerous Lesion.